TY - JOUR
T1 - Recommendations for probiotic use--2008.
AU - Floch, Martin H.
AU - Walker, W. Allan
AU - Guandalini, Stefano
AU - Hibberd, Patricia
AU - Gorbach, Sherwood
AU - Surawicz, Christina
AU - Sanders, Mary Ellen
AU - Garcia-Tsao, Guadalupe
AU - Quigley, Eamonn M.M.
AU - Isolauri, Erika
AU - Fedorak, Richard N.
AU - Dieleman, Levinus A.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2008/7
Y1 - 2008/7
N2 - Recommendations for the clinical use of probiotics were published after a Yale University Workshop in 2005. A similar workshop was held in 2007, and the recommendations were updated and extended into other areas. The recommendations are graded into an "A," "B," "C" or no category based on the expert's opinion and review by the workshop participants. An "A" recommendation is made for acute childhood diarrhea, prevention of antibiotic-associated diarrhea, preventing and maintaining remission in pouchitis, and in an immune response for the treatment and prevention of atopic eczema associated with cow's milk allergy. The group maintained several "B" recommendations in other areas of treating inflammatory bowel disease and irritable bowel syndrome. Although there are significant studies in the "B" group, most "B" recommendations did not reach an "A" level because of some negative studies or a limited number of studies. Many reports in the "C" recommendations were significant but fell short of receiving stronger ratings because of the size of reported patient studies, and also the factors that limited categories to the "B" rating.
AB - Recommendations for the clinical use of probiotics were published after a Yale University Workshop in 2005. A similar workshop was held in 2007, and the recommendations were updated and extended into other areas. The recommendations are graded into an "A," "B," "C" or no category based on the expert's opinion and review by the workshop participants. An "A" recommendation is made for acute childhood diarrhea, prevention of antibiotic-associated diarrhea, preventing and maintaining remission in pouchitis, and in an immune response for the treatment and prevention of atopic eczema associated with cow's milk allergy. The group maintained several "B" recommendations in other areas of treating inflammatory bowel disease and irritable bowel syndrome. Although there are significant studies in the "B" group, most "B" recommendations did not reach an "A" level because of some negative studies or a limited number of studies. Many reports in the "C" recommendations were significant but fell short of receiving stronger ratings because of the size of reported patient studies, and also the factors that limited categories to the "B" rating.
UR - http://www.scopus.com/inward/record.url?scp=53149093660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53149093660&partnerID=8YFLogxK
M3 - Review article
C2 - 18542033
AN - SCOPUS:53149093660
SN - 0192-0790
VL - 42 Suppl 2
SP - S104-108
JO - Journal of Clinical Gastroenterology
JF - Journal of Clinical Gastroenterology
ER -